ALK and neoplasm: After the progression, the molecular testing revealed <i>CCDC6-RET</i> fusion in a liver metastasis, two novel <i>RET</i> fusions (<i>IL6ST-RET</i> and <i>SLC41A3-RET</i>), and an <i>ALK</i> fusion with a mutation allele frequency of 0.19% in circulating tumor DNA (ctDNA), including the known <i>EGFR</i> 19del.